Skip to main content
UCB logo

UCB — Investor Relations & Filings

Ticker · UCB ISIN · BE0003739530 LEI · 2138008J191VLSGY5A09 BR Manufacturing
Open in API
Filings indexed 2,023 across all filing types
Latest filing 2014-07-30 Interim / Quarterly Rep…
Country BE Belgium
Listing BR UCB

About UCB

https://www.ucb.com/

UCB is a global biopharmaceutical company that focuses on creating solutions for people living with severe diseases, primarily in the fields of neurology and immunology. The company's core activities include the research, development, and commercialization of pharmaceutical and biotechnology products. Guided by a patient-centric and science-driven approach, UCB is committed to innovation and sustainability. Through its UCB Ventures arm, it invests in pioneering technologies and companies with the potential to transform patient care. The company also offers personalized support services to patients and healthcare professionals during their treatment journey with a UCB medicine.

Recent filings

Filing Released Lang Actions
2014 HY management report - ENG - final.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a '2014 half-year management report' which includes detailed financial statements, condensed consolidated income statements, balance sheets, cash flow statements, and management's discussion and analysis of financial performance for the first six months of the year. It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). H1 2014
2014-07-30 English
2014 HY management report - FR - final.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a 'Rapport de gestion du premier semestre 2014' (Management Report for the first half of 2014) published on July 30, 2014. It contains comprehensive financial statements, including consolidated income statements, balance sheets, cash flow statements, and detailed notes to the financial statements for the six-month period. Since it covers a period shorter than a full fiscal year and includes substantive financial data and analysis, it is classified as an Interim/Quarterly Report. H1 2014
2014-07-30 French
2014 HY management report - NL - final.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a 'Halfjaarlijks financieel verslag' (Half-year financial report) for the period ending June 30, 2014. It contains comprehensive financial statements, including a consolidated income statement, balance sheet, cash flow statement, and detailed management analysis of business performance, revenue, and outlook. As it covers a period shorter than a full fiscal year and includes substantive financial data, it is classified as an Interim/Quarterly Report. H1 2014
2014-07-30 Dutch
Positive topline Phase 3 results for brivaracetam in epilepsy
Earnings Release Classification · 99% confidence The document is a press release dated July 23, 2014, announcing positive topline Phase 3 results for the drug 'brivaracetam' in epilepsy patients. It details clinical trial outcomes, mentions plans for regulatory submissions (FDA/EMA) in early 2015, and includes standard corporate boilerplate, forward-looking statements, and contact information. This format—a formal announcement of significant operational/clinical news, often marked as 'regulated information'—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it focuses specifically on the release of key financial/clinical results (Phase 3 success) rather than a full quarterly report (IR) or a transcript (CT), it aligns best with an Earnings Release (ER) which covers period results/milestones. Given the context of a major clinical milestone announcement, ER is the most appropriate fit over the general RNS. Q3 2014
2014-07-23 English
Premiers résultats de phase 3 positifs pour le brivaracetam en epilepsie
Regulatory Filings Classification · 95% confidence The document is a press release dated July 23, 2014, announcing positive Phase 3 trial results for the drug 'brivaracetam' for epilepsy. It details the study design, efficacy, safety profile, and explicitly states that regulatory submissions (NDA to FDA and MAA to EMA) are planned for early 2015. The text is a detailed announcement of clinical trial progress and future regulatory steps, not a formal regulatory filing like a 10-K, an earnings release (ER), or a formal report (AR/IR). It functions as a major corporate/R&D update aimed at investors and the public. Given the content focuses on clinical trial data and upcoming regulatory filings, it best fits the category for general corporate/regulatory announcements that are not covered by more specific codes. Since it is a detailed announcement of R&D progress and future plans, and not a formal financial report or a transcript, the most appropriate classification among the options is 'Regulatory Filings' (RNS) as a general regulatory announcement, or potentially 'Earnings Release' (ER) if it were tied to a quarterly report, but it is clearly focused on R&D milestones. However, since it is a press release announcing clinical trial success and upcoming regulatory submissions, it is a significant corporate communication. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal Financial Report (10-K/IR). It is a specific type of corporate news release. Given the options, 'RNS' (Regulatory Filings - general regulatory announcements and fallback) is the best fit for a press release detailing clinical trial results and future regulatory plans, especially since it is labeled 'information réglementée'.
2014-07-23 French
Positieve topline fase 3-resultaten voor brivaracetam inepilepsie
Earnings Release Classification · 99% confidence The document is a press release dated July 23, 2014, originating from UCB, announcing positive topline Phase 3 results for the drug *brivaracetam* in epilepsy patients. It details clinical trial outcomes, mentions plans to file for regulatory approval with the FDA and EMA in early 2015, and includes standard sections like 'About UCB' and 'Forward-Looking Statements'. This format—an immediate announcement of key results, often including financial or operational milestones, but not the full, comprehensive financial report (like a 10-K or IR)—is characteristic of an Earnings Release (ER) or a significant operational update. Since this focuses specifically on clinical trial success and regulatory filing timelines rather than quarterly financial performance highlights, it aligns best with a major operational/research update. However, among the provided codes, 'ER' (Earnings Release) is often used broadly for initial results announcements, but 'RPA' (Report Publication Announcement) is for announcing *other* reports. Given the content is the *result itself* (the positive trial data) presented as a news release, and it is not a standard regulatory filing like 10-K or IR, it most closely resembles an Earnings Release (ER) in structure (a press release announcing key period results/milestones), or potentially a Regulatory Filing (RNS) if it were less specific. Since it is a direct announcement of a major operational/clinical milestone, 'ER' is the closest fit for a time-sensitive, results-focused press release, although 'RNS' is a possibility if it were purely regulatory. Given the focus on clinical trial results and future regulatory submissions, it is a significant corporate announcement, best categorized as an Earnings Release (ER) as it announces a major 'result' for the R&D pipeline, or RNS as a general regulatory announcement. Given the structure and timing (press release format), ER is slightly more appropriate than the general RNS fallback, as it is reporting a key 'result'. I will classify it as ER, as it is a release of key performance indicators (clinical trial success). Q3 2014
2014-07-23 Dutch

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.